GV and new strategic partner Centene both participated in a round that boosted the collaborative mental healthcare platform’s total funding to $153m.

Roche participated in the Agilent Technologies-led round, which will fund the launch of Stanford spinout Purigen's isotachophoresis-based DNA and RNA sample preparation platform.

The neurobehavioural disorder drug developer sourced funding from investors including Scripps Research, Alphabet, Alexandra Real Estate Equities and Johnson & Johnson in the round.

Roche also participated in the Agilent Technologies-led round, which will fund the launch of Purigen's isotachophoresis-based DNA and RNA sample preparation platform.

Johnson & Johnson Innovation – JJDC contributed to Artizan Biosciences' series A round while Brii Biosciences invested through a licensing deal.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Dundee-founded drug discovery company Exscientia has entered into a collaboration agreement with GT Apeiron, whose parent GT Healthcare invested in the spinout’s series B round.

General Electric had considered spinning out its corporate venturing operation, but has now shifted its focus to finding a buyer for a portfolio consisting of stakes in more than 100 companies.

Sanford Health has provided $23m in funding to increase the regenerative cell therapy provider's series D round to $43m, having initially supplied the first $20m in 2017.

Insurance firms and strategic partners Dai-ichi Life and Sompo Holding helped digital health tool developer Neurotrack increase its total funding to more than $51m.